Making Psychedelics Mainstream & Accessible | Delic Corp

By |

Watch

Midas Letter

The Digital Businesss Channel for Cannabis, Crypto and Technology Stocks.

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

Midas Letter
Midas Letter
Making Psychedelics Mainstream & Accessible | Delic Corp
/

Former owner of High Times, the most recognized media brand in cannabis, has shifted his focus to making psychedelics mainstream and accessible. Having already helped grow the legal cannabis industry over the last two decades Matt Stang aims to do the same in psychedelics as they follow a similar path towards legalization.

Delic Holdings Inc (OTCMKTS:DELCF, CNSX:DELC) is a first-of-its-kind global psychedelic wellness company working towards treating mental health issues and helping people get well using psychedelic medicines. Delic plans to become the largest ketamine provider in the USA having acquired a chain of ketamine clinics in the southwest.

Ketamine has been used safely as an anesthetic over the last sixty years. Doctors have described its effects for patients suffering from PTSD, anxiety, depression, and other mental health illnesses as a “reset” – providing relief of symptoms and allowing patients to experience a shift in their mental wellbeing.

Delic already has built an infrastructure with cashflows of a successful business and is not just a biotech business with a decade-long road to potential revenue.

“[Ketamine] is the only legal psychedelic right now. We are working on obviously psilocybin and MDMA coming out behind it, but we think ketamine on its own is an incredibly powerful and beneficial substance… Pharmaceutical companies have no substance the helps people. The current crop of pharmaceuticals only has a 4-5% improvement. When you look at things and there’s something an order of magnitude better: this will win and will take over the world.”

“We want to be the infrastructure play, the cashflow play for psychedelics. We have clinics and cash flow that make millions of dollars. We really want to show people the opportunity to invest in that infrastructure play around psychedelic wellness.” – Delic Corp CEO Matt Stang

Watch the full interview to learn how ketamine is used to help mental health and how Delic has set up its infrastructure to help bring psychedelics into the mainstream.

Transcript

00:29 – Delic business overview

01:13 – Ketamine medical use

04:52 – How many patients ketamine clinics treat

06:45 – Delic ecosystem

07:35 – High Times

08:11 – Ketamine patient experience

12:22 – Mainstream & accessibility of Delic’s psychedelic medicines

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.